In the evolving landscape of diabetes management, novel treatments like semaglutide and retatrutide are gaining traction. These agents, belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist group, offer https://flynnkotx557266.wikiparticularization.com/user